home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

88.85 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, May 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

72 73 Next >

What's Going On With BioNTech (BNTX) Stock? ↗

August 09, 2023

BioNTech SE - ADR (NASDAQ:BNTX) shares are trading higher by 4.66% to $106.51 Wednesday morning as the stock continues to rebound after falling on Monday.

Via Benzinga

What's Happening With BioNTech (BNTX) Stock? ↗

August 08, 2023

BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 3.28% to $101.73 Tuesday afternoon as the stock rebounds after falling on Monday.

Via Benzinga

BioNTech Se (BNTX) Q2 2023 Earnings Call Transcript ↗

August 07, 2023

BNTX earnings call for the period ending June 30, 2023.

Via The Motley Fool

Why BioNTech Stock Was Sinking Today ↗

August 07, 2023

While the waning of the COVID pandemic is a positive development for the world, it's left the German biotech struggling.

Via The Motley Fool

Why Moderna Stock Sunk Today ↗

August 07, 2023

Moderna, Inc. (NASDAQ: MRNA) shares are trading lower on Monday.

Via Benzinga

PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories ↗

August 07, 2023

Benzinga

Via Benzinga

BioNTech Skids As Covid Vaccine-Maker's Sales Plummet And Miss Forecasts ↗

August 07, 2023

The company kept its sales outlook for the year, however.

Via Investor's Business Daily

Preview: BioNTech's Earnings ↗

August 04, 2023

Via Benzinga

Analyst Ratings for BioNTech ↗

August 01, 2023

Via Benzinga

BioNTech Slips Into Quarterly Loss As Q2 Revenue Evaporates, Cuts R&D Spending For FY23 ↗

August 07, 2023

BioNTech SE (NASDAQ: BNTX) has reported Q2 revenues of €167.7 million, sharply down from €3.2 billion a year ago

Via Benzinga

US Stocks Eye Rebound After Big Earnings, But Inflation Data Looms: Analyst Says 3 Factors Can Take S&P 500 Past 4,800 ↗

August 07, 2023

US stocks look set for a cautious start as the week's inflation data will likely keep traders on tenterhooks.

Via Benzinga

BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update

August 07, 2023

From BioNTech SE

Via GlobeNewswire

Pfizer, Moderna Try To Squeeze Blood From A Stone. Why It Probably Won't Work. ↗

August 03, 2023

The company hopes to launch an updated Covid booster shot this fall. But there are several complications.

Via Investor's Business Daily

Week In Review: BeiGene Options DualityBio ADC In $1.3 Billion Agreement ↗

July 15, 2023

Deals and financings, trials and approvals in the Chinese biotech/biopharma sphere.

Via Talk Markets

Expert Ratings for BioNTech ↗

July 14, 2023

Via Benzinga

Price Over Earnings Overview: BioNTech ↗

June 29, 2023

Via Benzinga

Where BioNTech Stands With Analysts ↗

June 20, 2023

Via Benzinga

BioNTech Completes Acquisition of InstaDeep

July 31, 2023

From BioNTech SE

Via GlobeNewswire

Analyst Initiates Arcturus: Sees Attractive Growth Trajectory with Vaccine Franchise Despite Competition ↗

July 24, 2023

William Blair analyst Myles Minter has initiated coverage of Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) with an Outperform rating and a fair

Via Benzinga

BioNTech to Report Second Quarter 2023 Financial Results and Operational Update on August 7, 2023

July 24, 2023

From BioNTech SE

Via GlobeNewswire

Week In Review: Novartis In $1 Billion Deal For DTx Pharma ↗

July 22, 2023

Novartis signed a $1 billion agreement to acquire DTx Pharma, a preclinical San-Diego company developing siRNA therapies for neuroscience indications. Meanwhile, Zhuhai Biotheus formed a far-reaching...

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2023 ↗

July 14, 2023

Via Benzinga

3 Biotech Stocks That AI is Loving in July ↗

July 12, 2023

As AI becomes a more entrenched aspect of society, investors can lean on these AI recommended biotech stocks with predicted high potential.

Via InvestorPlace

Why These 7 Stocks Are the Best Ways to Play Biotech Right Now ↗

July 11, 2023

With biotech stocks offering myriad viable opportunities irrespective of broader conditions, this sector is worth a closer look.

Via InvestorPlace

Pfizer, European Pharma Firms Collaborate With European Commission For Future Health Emergency Preparedness ↗

June 30, 2023

The European Commission has reportedly made arrangements with Pfizer Inc (NYSE: PFE) and various European pharmaceutical companies to secure the capacity to produce up to 325 million vaccines annually...

Via Benzinga

BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC

June 29, 2023

From BioNTech SE

Via GlobeNewswire

Big Tech on the Prowl: 3 Potential AI Stock Acquisition Targets ↗

June 27, 2023

With the artificial intelligence boom gaining momentum, we’re likely to see far more interest in AI stocks.

Via InvestorPlace

Post-COVID-19: How the COVAX Initiative Could Redirect its $2.6B Surplus to Fight Future Pandemics ↗

June 26, 2023

As the emergency phase of the COVID-19 pandemic draws to a close, the COVAX initiative, run by Gavi, the WHO, and CEPI, reportedly has $2.6 billion left over that could be used to prepare for other...

Via Benzinga

Pfizer, Moderna, and Novavax Gear Up for XBB.1.5 Strain Targeted Vaccines as FDA AdCom Unanimously Support ↗

June 16, 2023

Thursday, the FDA's Vaccines and Related Biological Products Advisory Committee all 21 members v

Via Benzinga

Broadcom Might Receive European Approval For $61B VMware Deal, UBS Closes Credit Suisse Takeover, Illumina CEO Steps Down Amid Activist Investor Carl Icahn's Pressure: Today's Top Stories ↗

June 12, 2023

Reuters Broadcom Most Likely To Receive EU Approval For $61B VMware Merger

Via Benzinga

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

72 73 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com